Oxford BioMedica appoints John Dawson CEO
This article was originally published in Scrip
The UK gene therapy company Oxford BioMedicahas appointed John Dawson as permanent chief executive officer; he has served as acting CEO since August 29th. From 1996 to 2007, Mr Dawson held senior management positions in the European operations of Cephalon, including from 2005 as chief financial officer and head of business development Europe.
You may also be interested in...
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.
The Stark Law ban on self-referrals wouldn’t apply to some physician owners of advanced imaging facilities under a CMS final rule.
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.